MEDS DataMEDS AI, Inc.
DataMEDS AI, Inc. operates as a health IT company in the United States. The company focuses on the vertical integration of technology, pharmacy, pharmaceutical-adjacent, and telemedicine business units to deliver an enha…
Industry Peers
Medical Distribution| Headline | Source | Time |
|---|---|---|
Older | ||
Update: US Equity Indexes Fall as Iran Talks Stall, Fed Governor Points to Higher Rates, Inflation (Updates with index/price action, macroeconomic data, corporate developments, company/geopolitical n | ||
 Axe Compute Just Sold Its Cancer Business to Become an AI Stock Axe Compute stock has rallied over 650% in the past six months as investors increasingly value it as an AI infrastructure stock. The challenge is now delivering on that promise. | ||
 DataMeds AI Launches Health Lives Here App Focused on GLP-1 Telehealth and Pharmacy Services DataMeds AI (NASDAQ:MEDS) and Tollo Health launched the Health Lives Here mobile application, combining GLP-1 telehealth, pharmacy services, nutritional products and health tracking as part of a planned broader healthcare network. Key Investor TakeawaysDataMeds AI (NASDAQ:MEDS) and Tollo Health have launched Health Lives Here, initially targeting patients using GLP-1 receptor agonist medications. | ||
DataMeds AI stock rises on health app launch Investing.com -- DataMeds AI Inc (NASDAQ:MEDS) shares jumped 25% Monday following the launch of its Health Lives Here mobile application in partnership with Tollo Health. | ||
 Why DataMEDS’ Acquisition Does Not Seem to Be Very Bullish for MEDS Stock at This Point The low purchase price of Helomics and low revenue suggest that the acquisition is not that promising for DataMEDS AI. | ||
Sector Update: Healthcare Stocks Edge Lower Late Afternoon Healthcare stocks were slightly lower late Wednesday afternoon, with the NYSE Healthcare Index fract | ||
 DataMEDS AI Completes $1.5 Million Helomics Acquisition, Expanding into Cancer Diagnostics The transaction adds a certified oncology laboratory, contract research services and $1. 5 million in cash to DataMEDS, while Axe Compute exits its remaining cancer testing business. | ||